{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:16:40Z","timestamp":1760426200678,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100021069","name":"Indivior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40261-024-01347-1","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T18:02:40Z","timestamp":1708624960000},"page":"251-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients"],"prefix":"10.1007","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct03978832","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David P.","family":"Walling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita N.","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice M.","family":"Pogoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jahnavi","family":"Kharidia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8345-5980","authenticated-orcid":false,"given":"Celine M.","family":"Laffont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"issue":"10100","key":"1347_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(17)32154-2.","journal-title":"Lancet"},{"issue":"6","key":"1347_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195\u2013203. https:\/\/doi.org\/10.1093\/schbul\/sby058.","journal-title":"Schizophr Bull"},{"issue":"10","key":"1347_CR3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S0006-3223(99)00059-1","volume":"46","author":"JM Kane","year":"1999","unstructured":"Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999;46(10):1396\u2013408.","journal-title":"Biol Psychiatry"},{"key":"1347_CR4","first-page":"1163","volume":"13","author":"MC Mauri","year":"2014","unstructured":"Mauri MC, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163.","journal-title":"EXCLI J"},{"key":"1347_CR5","unstructured":"RISPERDAL\u00ae. Package insert. Janssen Pharmaceuticals, Inc, Titusville, New Jersey; 2007."},{"key":"1347_CR6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/PPA.S53795","volume":"7","author":"G Kaplan","year":"2013","unstructured":"Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171\u201380. https:\/\/doi.org\/10.2147\/PPA.S53795.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"1347_CR7","first-page":"266","volume":"5","author":"P Chue","year":"2005","unstructured":"Chue P, Llorca P, Duchesne I, Leal A, Rosillon D, Mehnert A. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res. 2005;5(2):266\u201374.","journal-title":"J Appl Res"},{"key":"1347_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1471-244X-11-168","volume":"11","author":"C Crivera","year":"2011","unstructured":"Crivera C, DeSouza C, Kozma CM, Dirani RD, Mao L, Macfadden W. Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE). BMC Psychiatry. 2011;11:168. https:\/\/doi.org\/10.1186\/1471-244X-11-168.","journal-title":"BMC Psychiatry"},{"issue":"5","key":"1347_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","volume":"35","author":"D Lin","year":"2021","unstructured":"Lin D, Thompson-Leduc P, Ghelerter I, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35(5):469\u201381. https:\/\/doi.org\/10.1007\/s40263-021-00815-y.","journal-title":"CNS Drugs"},{"issue":"4","key":"1347_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4088\/jcp.v65n0412","volume":"65","author":"HA Nasrallah","year":"2004","unstructured":"Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry. 2004;65(4):531\u20136. https:\/\/doi.org\/10.4088\/jcp.v65n0412.","journal-title":"J Clin Psychiatry"},{"key":"1347_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1471-244X-11-167","volume":"11","author":"W Macfadden","year":"2011","unstructured":"Macfadden W, DeSouza C, Crivera C, et al. Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. BMC Psychiatry. 2011;11:167. https:\/\/doi.org\/10.1186\/1471-244X-11-167.","journal-title":"BMC Psychiatry"},{"key":"1347_CR12","unstructured":"PERSERIS\u00ae. Package insert. Indivior Inc, North Chesterfield, Virginia; 2019."},{"issue":"2","key":"1347_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/JCP.0000000000000479","volume":"36","author":"AF Nasser","year":"2016","unstructured":"Nasser AF, Henderson DC, Fava M, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter Phase 3 study. J Clin Psychopharmacol. 2016;36(2):130\u201340. https:\/\/doi.org\/10.1097\/JCP.0000000000000479.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"1347_CR14","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1111\/bcp.13246","volume":"83","author":"V Ivaturi","year":"2017","unstructured":"Ivaturi V, Gopalakrishnan M, Gobburu JVS, et al. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting ATRIGEL formulation of risperidone. Br J Clin Pharmacol. 2017;83(7):1476\u201398. https:\/\/doi.org\/10.1111\/bcp.13246.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1347_CR15","doi-asserted-by":"publisher","first-page":"21m13906","DOI":"10.4088\/JCP.21m13906","volume":"82","author":"A Le Moigne","year":"2021","unstructured":"Le Moigne A, Csernansky J, Leadbetter RA, et al. PANSS individual item and Marder dimension analyses from a pivotal trial of RBP-7000 (monthly extended-release risperidone) in schizophrenia patients. J Clin Psychiatry. 2021;82(5):21m13906. https:\/\/doi.org\/10.4088\/JCP.21m13906.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1347_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/JCP.0000000000001076","volume":"39","author":"A Andorn","year":"2019","unstructured":"Andorn A, Graham J, Csernansky J, et al. Monthly extended-release risperidone (RBP-7000) in the treatment of schizophrenia: results from the Phase 3 program. J Clin Psychopharmacol. 2019;39(5):428\u201333. https:\/\/doi.org\/10.1097\/JCP.0000000000001076.","journal-title":"J Clin Psychopharmacol"},{"issue":"1\u20133","key":"1347_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.schres.2016.03.020","volume":"174","author":"JJ Isitt","year":"2016","unstructured":"Isitt JJ, Nadipelli VR, Kouassi A, Fava M, Heidbreder C. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: an 8-week, randomized, double-blind, placebo-controlled, multicenter Phase 3 study. Schizophr Res. 2016;174(1\u20133):126\u201331. https:\/\/doi.org\/10.1016\/j.schres.2016.03.020.","journal-title":"Schizophr Res"},{"key":"1347_CR18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2147\/PPA.S202173","volume":"13","author":"R Dhanda","year":"2019","unstructured":"Dhanda R, Varghese D, Nadipelli VR, et al. Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study. Patient Prefer Adherence. 2019;13:1037\u201350. https:\/\/doi.org\/10.2147\/PPA.S202173.","journal-title":"Patient Prefer Adherence"},{"key":"1347_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","volume":"14","author":"WF Richter","year":"2012","unstructured":"Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012;14:559\u201370.","journal-title":"AAPS J"},{"key":"1347_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jconrel.2021.06.038","volume":"336","author":"P Zou","year":"2021","unstructured":"Zou P, Wang F, Wang J, Lu Y, Tran D, Seo SK. Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins. J Control Release. 2021;336:310\u201321.","journal-title":"J Control Release"},{"key":"1347_CR21","doi-asserted-by":"crossref","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, Rockville, Maryland; 1976; p. 76-338.","DOI":"10.1037\/e591322011-001"},{"key":"1347_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11\u20139. https:\/\/doi.org\/10.1111\/j.1600-0447.1970.tb02066.x.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"1347_CR23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672\u20136. https:\/\/doi.org\/10.1192\/bjp.154.5.672.","journal-title":"Br J Psychiatry"},{"issue":"7","key":"1347_CR24","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","volume":"164","author":"K Posner","year":"2007","unstructured":"Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA\u2019s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035\u201343. https:\/\/doi.org\/10.1176\/ajp.2007.164.7.1035.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1347_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376. https:\/\/doi.org\/10.1093\/schbul\/13.2.261.","journal-title":"Schizophr Bull"},{"issue":"6","key":"1347_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40262-014-0132-7","volume":"53","author":"CM Laffont","year":"2014","unstructured":"Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014;53(6):533\u201343. https:\/\/doi.org\/10.1007\/s40262-014-0132-7.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1347_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/schbul\/sbx090","volume":"44","author":"T Kishimoto","year":"2018","unstructured":"Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018;44(3):603\u201319. https:\/\/doi.org\/10.1093\/schbul\/sbx090.","journal-title":"Schizophr Bull"},{"issue":"11","key":"1347_CR28","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/jamapsychiatry.2021.2130","volume":"78","author":"S Leucht","year":"2021","unstructured":"Leucht S, Bauer S, Siafis S, et al. Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis. JAMA Psychiat. 2021;78(11):1238\u201348. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.2130.","journal-title":"JAMA Psychiat"},{"issue":"1","key":"1347_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/nedt.2007.3.1.13","volume":"3","author":"P Chue","year":"2007","unstructured":"Chue P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat. 2007;3(1):13\u201339. https:\/\/doi.org\/10.2147\/nedt.2007.3.1.13.","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01347-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T02:19:07Z","timestamp":1711765147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01347-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1347"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01347-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"22 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Indivior Inc., North Chesterfield, VA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SNS, JMP, and CLM are employees of Indivior. JK was an Indivior employee at the time of the study. DPW reports grants from AbbVie, Acadia, Alkermes, Allergan, Avanir, Biogen Boehringer Ingelheim, Cerevel, CoMentis, Intra-Cellular Therapies, Indivior, Janssen, Johnson & Johnson PRD, Lundbeck, Lupin, Merck, Novartis, Noven, Otsuka, Prothena, Pfizer, Roche, Sunovion, and Takeda and personal fees from Janssen, Otsuka, Boehringer Ingelheim, Biogen Merck, and Lyndra.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data are available from the authors upon reasonable request. All requests for raw and analyzed data will be promptly reviewed by the sponsor delegate to verify if the request is subject to any confidentiality obligations. Patient-related data not included in the paper were generated as part of clinical trials and may be subject to patient confidentiality. Any data that can be shared will be released via a data use agreement.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"The study was approved by the local ethics committee on 18 June 2019 and was registered at ClinicalTrials.gov (identifier: NCT03978832).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"SNS, JMP, JK, and CLM contributed to the study design and data analysis. DPW conducted the study. All authors were involved in the interpretation of the data and critically reviewed the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"All participants provided written informed consent before screening procedures.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}